glp-1 litigation news today A federal judge on Wednesday dismissed part of Eli Lilly's lawsuit against the Houston-based Empower Pharmacy — the latest development in the pharmaceutical giant's bid to curb sales of cheaper, less-regulated versions GLP-1 Compounding Crackdown | Double-Helix

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

A new review from the Schmidt lab at Penn pulls the preclinical and emerging clinical evidence together

Why? Fatigue is a frequent complaint for those on GLP-1 medications

This multi-strain probiotic is formulated with beneficial bacteria that naturally increase GLP-1, the un-hunger hormone that helps curb cravings & appetite

Confused about where to start your metabolic health journey

The booming GLP-1 market, projected to reach $167bn by 2031, presents compelling opportunities for private equity players to carve out their niche and capture substantial value, despite industry giants Novo Nordisk and Eli Lilly dominating the lions share of the market. Download PDF